Induction of the mitochondria apoptosis pathway by phytohemagglutinin erythroagglutinating in human lung cancer cells

Annals of Surgical Oncology

Volumn 18, Issue 3, 2011, Pages 848-856

  Kuo, Wei Ting ^a   Ho, Yung Jen ^a   Kuo, Shyh Ming ^b   Lin, Feng Huei ^c   Tsai, Fuu Jen ^a   Chen, Yueh Sheng ^a   Dong, Guo Chung ^c   Yao, Chun Hsu ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROAGGLUTINATING; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT LECTIN; PROPIDIUM IODIDE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME RELEASE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MITOCHONDRION; NICK END LABELING; NITROBLUE TETRAZOLIUM TEST; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CYTOCHROMES C; GLUCOSEPHOSPHATE DEHYDROGENASE; HUMANS; LUNG NEOPLASMS; MITOCHONDRIA; PHYTOHEMAGGLUTININS; SIGNAL TRANSDUCTION;

EID: 79955719652     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1351-2     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
3. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18:1059-68. (Pubitemid 34092881)
4. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003;4:721-9. (Pubitemid 37527207)
5. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-57.
6. Lockshin RA, Zakeri Z. Programmed cell death and apoptosis: Origins of the theory. Nat Rev Mol Cell Biol. 2001;2:545-50. (Pubitemid 33673405)
7. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-12. (Pubitemid 28406816)
8. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269-90. (Pubitemid 32250377)
9. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem. 2000;69:217-45.
10. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol. 2000;10:369-77. (Pubitemid 30612469)
11. Ozören N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol. 2003;13:135-47. (Pubitemid 36321814)
12. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324-37. (Pubitemid 46328466)
13. Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47-59.
14. Zornig M, Hueber A, Baum W, Evan G. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta. 2001;1551: F1-37.
15. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell. 2004;116:205-19. (Pubitemid 38167313)
16. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5:876-85. (Pubitemid 41746032)
17. Khan N, Afaq F, Mukhtar H. Apoptosis by dietary factors: The suicide solution for delaying cancer growth. Carcinogenesis. 2007;28:233-9. (Pubitemid 46321838)
18. De Mejía EG, Prisecaru VI. Lectins as bioactive plant proteins: A potential in cancer treatment. Crit Rev Food Sci Nutr. 2005;45:425-45. (Pubitemid 43203787)
19. Leavitt RD, Feldsted RL, Bachur NR. Biological and biochemical properties of Phaseolus vulgaris. isolectins. J Biol Chem. 1977;252:2961-6. (Pubitemid 8096456)
20. Rüdiger H, Gabius HJ. Plant lectins: Occurrence, biochemistry, functions and applications. Glycoconj J. 2001;18:589-613. (Pubitemid 35341855)
21. Zhang JS, Shi J, Ilic S, Xue SJ, Kakuda Y. Biological properties and characterization of lectin from red kidney bean (Phaseolus vulgaris.). Food Rev Int. 2009;25:12-27.
22. O'Flynn K, Krensky AM, Beverley PC, Burakoff SJ, Linch DC. Phytohaemagglutinin activation of T cells through the sheep red blood cell receptor. Nature. 1985;313:686-7. (Pubitemid 15172474)
23. Yashwantrai NV, Flossie WS. The biochemistry of AIDS. Annu Rev Biochem. 1991;60:577-630.
24. Ye XY, Ng TB, Tsang WK, Wang J. Isolation of a homodimeric lectin with antifungal and antiviral activities from red kidney bean (Phaseolus vulgaris.) seeds. J Protein Chem. 2001;20:367-75.
25. Kiss R, Camby I, Duckworth C, et al. In vitro influence of Phaseolus vulgaris, Griffonia simplicifolia,. concanavalin A, wheat germ, and peanut agglutinins on HCT-15, LoVo, and SW837 human colorectal cancer cell growth. Gut. 1997;40:253-61. (Pubitemid 27093103)
26. De Mejía EG, Prisecaru VI. Lectins as bioactive plant proteins: A potential in cancer treatment. Crit Rev Food Sci Nutr. 2005; 45:425-45. (Pubitemid 43203787)
27. Wimer BM. Therapeutic activities of PHA-L4, the mitogenic isolectin of phytohemagglutinin. Mol Biother. 1990;2:74-90.
28. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006;6:876-85. (Pubitemid 44629899)
29. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992;11:121-39.
30. Handerson T, Camp R, Harigopal M, Rimm D, Pawelek J. Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res. 2005;11:2969-73. (Pubitemid 40525200)
31. Rebbaa A, Chou PM, Vucic I, et al. Expression of bisecting GlcNAc in pediatric brain tumors and its association with tumor cell response to vinblastine. Clin Cancer Res. 1999;5:3661-8.
32. Von Ahsen O, Waterhouse NJ, Kuwana T, Newmeyer DD, Green DR. The "harmless" release of cytochrome c.. Cell Death Differ. 2000;7:1192-9.
33. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta. 2004;1644:107-13. (Pubitemid 38281267)
34. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647-56. (Pubitemid 37328916)
35. Fletcher JI, Meusburger S, Hawkins CJ, et al. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci USA. 2008;105:18081-7.
36. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996;87:619-28. (Pubitemid 26386936)
37. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393-403. (Pubitemid 40193310)
38. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315:856-9.
39. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-41. (Pubitemid 27456390)
40. Datta SR, Ranger AM, Lin MZ, et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell. 2002;3:631-43. (Pubitemid 35339482)
41. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65:1566-84.
42. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res. 2006;12:5268-72. (Pubitemid 44497237)
43. Lacroix L, Besse B, Bidart JM, Bosq J. KRAS status versus EGFR status in lung cancer therapy. Bull Cancer. 2009;96:S75-83.
44. Mukohara T, Kudoh S, Yamauchi S, et al. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer. 2003;41:123-30. (Pubitemid 36842775)
45. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa," ZD1839). Oncol Rep. 2004;12:1053-7.